NEW YORK (GenomeWeb News) – The University of Maryland Biotechnology Institute said Monday that it has spun out a proteomics venture that will commercialize protein characterization and quantification technology.

The new Rockville-based company, called Omic Biosystems, will market a technology called DiART (deuterium (2H) isobaric amine reactive tags) that uses protein tagging designs coupled with sample preparation technology for use in large-scale mass spectrometry proteomics studies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.